Basic overview of current immunotherapy approaches in urologic malignancy

Charles G. Drake

Research output: Contribution to journalArticle

Abstract

The immune response to evolving prostate cancer is a complex and carefully orchestrated process. Such a response is initiated when immature dendritic cells take up and process tumor-associated antigens. These dendritic cells must then be activated in order to present peptides to helper (CD4) T cells. Cytolytic (CD8) T cells are next "licensed" to achieve full effector function by interacting with both antigen presenting cells and tumor-specific CD4 T cells. Finally, activated CD8 T cells traffic to sites of neoplasia and mediate killing by multiple mechanisms. This article provides a basic overview of these processes, and discusses the manner by which current clinical interventions seek to augment or initiate an antitumor immune response. Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Immunotherapy
T-Lymphocytes
Dendritic Cells
Neoplasms
Neoplasm Antigens
Antigen-Presenting Cells
Helper-Inducer T-Lymphocytes
Prostatic Neoplasms
Down-Regulation
Peptides

Keywords

  • Immunology
  • Prostate
  • T cell
  • Tumor
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Basic overview of current immunotherapy approaches in urologic malignancy. / Drake, Charles G.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 24, No. 5, 09.2006, p. 413-418.

Research output: Contribution to journalArticle

@article{1f37781c545f4de2a5eb03f75290e5a4,
title = "Basic overview of current immunotherapy approaches in urologic malignancy",
abstract = "The immune response to evolving prostate cancer is a complex and carefully orchestrated process. Such a response is initiated when immature dendritic cells take up and process tumor-associated antigens. These dendritic cells must then be activated in order to present peptides to helper (CD4) T cells. Cytolytic (CD8) T cells are next {"}licensed{"} to achieve full effector function by interacting with both antigen presenting cells and tumor-specific CD4 T cells. Finally, activated CD8 T cells traffic to sites of neoplasia and mediate killing by multiple mechanisms. This article provides a basic overview of these processes, and discusses the manner by which current clinical interventions seek to augment or initiate an antitumor immune response. Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined.",
keywords = "Immunology, Prostate, T cell, Tumor, Vaccine",
author = "Drake, {Charles G.}",
year = "2006",
month = "9",
doi = "10.1016/j.urolonc.2005.08.013",
language = "English (US)",
volume = "24",
pages = "413--418",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Basic overview of current immunotherapy approaches in urologic malignancy

AU - Drake, Charles G.

PY - 2006/9

Y1 - 2006/9

N2 - The immune response to evolving prostate cancer is a complex and carefully orchestrated process. Such a response is initiated when immature dendritic cells take up and process tumor-associated antigens. These dendritic cells must then be activated in order to present peptides to helper (CD4) T cells. Cytolytic (CD8) T cells are next "licensed" to achieve full effector function by interacting with both antigen presenting cells and tumor-specific CD4 T cells. Finally, activated CD8 T cells traffic to sites of neoplasia and mediate killing by multiple mechanisms. This article provides a basic overview of these processes, and discusses the manner by which current clinical interventions seek to augment or initiate an antitumor immune response. Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined.

AB - The immune response to evolving prostate cancer is a complex and carefully orchestrated process. Such a response is initiated when immature dendritic cells take up and process tumor-associated antigens. These dendritic cells must then be activated in order to present peptides to helper (CD4) T cells. Cytolytic (CD8) T cells are next "licensed" to achieve full effector function by interacting with both antigen presenting cells and tumor-specific CD4 T cells. Finally, activated CD8 T cells traffic to sites of neoplasia and mediate killing by multiple mechanisms. This article provides a basic overview of these processes, and discusses the manner by which current clinical interventions seek to augment or initiate an antitumor immune response. Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined.

KW - Immunology

KW - Prostate

KW - T cell

KW - Tumor

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33748186518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748186518&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.08.013

DO - 10.1016/j.urolonc.2005.08.013

M3 - Article

C2 - 16962493

AN - SCOPUS:33748186518

VL - 24

SP - 413

EP - 418

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -